B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies
Background: Patients with primary antibody deficiencies are at risk in the current COVID-19 pandemic due to their impaired response to infection and vaccination. Specifically, patients with common variable immunodeficiency (CVID) generated poor spike-specific antibody and T cell responses after immu...
Guardado en:
Autores principales: | Federica Pulvirenti, Ane Fernandez Salinas, Cinzia Milito, Sara Terreri, Eva Piano Mortari, Concetta Quintarelli, Stefano Di Cecca, Gianluca Lagnese, Alessandra Punziano, Marika Guercio, Livia Bonanni, Stefania Auria, Francesca Villani, Christian Albano, Franco Locatelli, Giuseppe Spadaro, Rita Carsetti, Isabella Quinti |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/822e5cbd55774323bc3b29c8133a67df |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
por: Mohammad Shehab, et al.
Publicado: (2021) -
Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
por: Matteo Nioi, et al.
Publicado: (2021) -
Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
por: Hamad Ali, et al.
Publicado: (2021) -
Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
por: Rana Shibli, et al.
Publicado: (2021) -
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
por: Ilaria Vicenti, et al.
Publicado: (2021)